SCHEMBL24137483

SCHEMBL24137483

CC(=O)Nc1ccc(-c2cnc(NCc3ccccc3)nc2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.54
▸ VNN1 O95497 3/20 0.51
▸ HDAC3 O15379 4/20 0.50
▸ HDAC1 Q13547 3/20 0.50
▸ HDAC2 Q92769 3/20 0.50
▸ HDAC6 Q9UBN7 2/20 0.50
▸ PIK3CD O00329 1/20 0.47
▸ PIK3CG P48736 1/20 0.47
▸ APP P05067 1/20 0.47
▸ ACHE P22303 1/20 0.47
▸ ACACB O00763 2/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ BRAF P15056 1/20 0.46
▸ PTK2 Q05397 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24137837 0.83 BRAF (0.53) EGFRPIK3CDPIK3CGBRAFMEN1
SCHEMBL24137801 0.82 VNN1 (0.47) VNN1HDAC3HDAC1HDAC2HDAC6
SCHEMBL30338494 0.81 PTK2 (0.57) PIK3CDPIK3CGPTK2MEN1GAA
SCHEMBL25938463 0.77 BRAF (0.45) EGFRBRAF
SCHEMBL12001179 0.76 ACACB (0.73) VNN1HDAC3HDAC1HDAC2HDAC6
SCHEMBL10133044 0.75 ROCK2 (0.58) MEN1ALDH1A1LMNAKMT2A
SCHEMBL12001206 0.75 ACACB (0.74) ACACB
SCHEMBL17809713 0.75 DEGS1 (0.54) PIK3CDPIK3CGPTK2MEN1GAA
SCHEMBL22975368 0.74 PTK2 (0.56) PIK3CDPIK3CGPTK2GAAKMT2A
SCHEMBL23019453 0.73 MET (0.52) PIK3CDPIK3CGALDH1A1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
WO-2021263129-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 EGFR 800/4885VNN1 4618/4885HDAC3 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback